{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:42:36Z","timestamp":1770680556860,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["BYSYFY2021003"],"award-info":[{"award-number":["BYSYFY2021003"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170562"],"award-info":[{"award-number":["82170562"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.dld.2022.12.019","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:43:02Z","timestamp":1673656982000},"page":"601-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial"],"prefix":"10.1016","volume":"55","author":[{"given":"Zhiqiang","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojun","family":"Suo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueli","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanyue","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2022.12.019_bib0001","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in helicobacter pylori: a systematic review and meta-analysis in world health organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.019_bib0002","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.019_bib0003","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.019_bib0004","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.4103\/0366-6999.169107","article-title":"Helicobacter pylori and gastric cancer: clinical aspects","volume":"128","author":"Song","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.dld.2022.12.019_bib0005","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese national consensus report on the management of helicobacter pylori infection","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of helicobacter pylori infection-the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.019_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","article-title":"Tailored versus triple plus bismuth or concomitant therapy as initial helicobacter pylori treatment: a randomized trial","volume":"21","author":"Zhou","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0008","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3748\/wjg.v22.i19.4766","article-title":"Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"22","author":"Song","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.019_bib0009","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/gutjnl-2015-309900","article-title":"Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy","volume":"64","author":"Zhang","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.019_bib0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hel.12052","article-title":"Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy","volume":"18","author":"Liao","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0011","doi-asserted-by":"crossref","first-page":"e12768","DOI":"10.1111\/hel.12768","article-title":"The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy","volume":"26","author":"Ke","year":"2021","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0012","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cgh.2019.03.048","article-title":"Combination of Bismuth and standard triple therapy eradicates helicobacter pylori infection in more than 90% of patients","volume":"18","author":"McNicholl","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.12.019_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1469-0691.2009.02725.x","article-title":"Antibiotic consumption and link to resistance","volume":"15 Suppl 3","author":"Goossens","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dld.2022.12.019_bib0014","doi-asserted-by":"crossref","first-page":"524","DOI":"10.14309\/ajg.0000000000001659","article-title":"Antimicrobial susceptibility testing for helicobacter pylori is now widely available: when, how, why","volume":"117","author":"Graham","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.019_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of recent helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics","volume":"157","author":"Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.019_bib0016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.12.019_bib0017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.019_bib0018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.019_bib0019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","article-title":"Pharmacologic aspects of eradication therapy for helicobacter pylori infection","volume":"39","author":"Furuta","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.dld.2022.12.019_bib0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.14309\/ajg.0000000000000223","article-title":"Impact of previous exposure to macrolide antibiotics on helicobacter pylori infection treatment outcomes","volume":"114","author":"Boltin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.019_bib0021","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MCG.0000000000001237","article-title":"Effect of previous nitroimidazole treatment on helicobacter pylori eradication success","volume":"54","author":"Boltin","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.019_bib0022","first-page":"23","article-title":"Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens","author":"Munoz-Gomez","year":"2018","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0023","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.dld.2015.12.001","article-title":"The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use","volume":"48","author":"Lim","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2022.12.019_bib0024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/0003-4819-139-6-200309160-00008","article-title":"The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections","volume":"139","author":"McMahon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2022.12.019_bib0025","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/s41467-021-22557-7","article-title":"Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides","volume":"12","author":"Kocsmar","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.dld.2022.12.019_bib0026","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1523-5378.2002.00096.x","article-title":"The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance","volume":"7","author":"Perez Aldana","year":"2002","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0027","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1136\/gut.35.11.1562","article-title":"High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease","volume":"35","author":"Banatvala","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.019_bib0028","doi-asserted-by":"crossref","first-page":"e12773","DOI":"10.1111\/hel.12773","article-title":"Classification system for Helicobacter pylori therapies: compared and contrasted to traditional infectious disease therapy","volume":"26","author":"Graham","year":"2021","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0029","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14787210.2018.1511427","article-title":"Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies","volume":"16","author":"Graham","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.dld.2022.12.019_bib0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.gtc.2015.05.003","article-title":"How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly","volume":"44","author":"Graham","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.dld.2022.12.019_bib0031","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cgh.2021.03.026","article-title":"Primer for development of guidelines for helicobacter pylori therapy using antimicrobial stewardship","volume":"20","author":"Graham","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.12.019_bib0032","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994","volume":"20","author":"Dixon","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.dld.2022.12.019_bib0033","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/JLP.JLP_176_17","article-title":"Clinical and laboratory standards institute versus European committee for antimicrobial susceptibility testing guidelines for interpretation of carbapenem antimicrobial susceptibility results for Escherichia coli in urinary tract infection (UTI)","volume":"10","author":"Sahu","year":"2018","journal-title":"J Lab Physicians"},{"key":"10.1016\/j.dld.2022.12.019_bib0034","doi-asserted-by":"crossref","first-page":"e12762","DOI":"10.1111\/hel.12762","article-title":"A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial","volume":"25","author":"Song","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0035","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-2036.2012.05083.x","article-title":"Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?","volume":"35","author":"McNulty","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.12.019_bib0036","doi-asserted-by":"crossref","first-page":"e12694","DOI":"10.1111\/hel.12694","article-title":"Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: a real-life study","volume":"25","author":"Romano","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.dld.2022.12.019_bib0037","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12929-018-0471-z","article-title":"Toward population specific and personalized treatment of Helicobacter pylori infection","volume":"25","author":"Liou","year":"2018","journal-title":"J Biomed Sci"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822008672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822008672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:22:25Z","timestamp":1761625345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822008672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1590865822008672"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.12.019","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}